Skip to content

The role of 68Ga-FAPI PET/CT imaging in individualized diagnosis and treatment of platinum sensitive recurrent/suspected recurrent ovarian cancer patients

The role of 68Ga-FAPI PET/CT imaging in individualized diagnosis and treatment of platinum sensitive recurrent/suspected recurrent ovarian cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300079288
Enrollment
Unknown
Registered
2023-12-29
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platinum sensitive recurrence/suspected recurrence of ovarian cancer

Interventions

Sponsors

the First Affiliated Hospital of the People's Liberation Army Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Selection criteria: 1) Non mucinous ovarian epithelial carcinoma; 2) Sensitive to platinum based chemotherapy drugs. 3) Pathological or clinical follow-up confirms/suspects recurrence of ovarian cancer. 4) Age>18 years old,<80 years old; 5) Volunteer to participate and cooperate throughout the entire process to complete 18F-FDG and 68Ga-FAPI PET/CT imaging; 6) Sign an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1) Previous malignant tumors in other areas; 2) Mucinous cystadenocarcinoma or non epithelial ovarian cancer; 3) Platinum resistance; 4) Pathological or clinical exclusion of recurrence; 5) Unable to lie flat for 15-30 minutes; 6) Refusal to participate in the clinical trial or unsigned consent form.

Design outcomes

Secondary

MeasureTime frame
Gene mutation status (BRCA1/BRCA2/HRD/HRR);Tumor indicators before imaging (CA125/HE4);

Primary

MeasureTime frame
SUVmax;

Countries

China

Contacts

Public ContactXiang Li

the First Affiliated Hospital of the People's Liberation Army Air Force Military Medical University

xiangli1215225@163.com+86 155 2968 2261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026